Amylyx Pharmaceuticals, Inc. (AMLX) stock
AMLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$30.29+0.43 (+1.44%)
Close on Nov 13, 2026Market cap $3.38BP/E –Yield –
Amylyx Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Amylyx Pharmaceuticals's total assets was $786.80M at Sep 30, 2026. For fiscal 2025 it was $332.65M, up 71.8% from the year before. The highest annual figure on record is $517.45M in fiscal 2023.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $332.65M | +71.8% |
| FY2024 | Dec 31, 2024 | $193.63M | -62.6% |
| FY2023 | Dec 31, 2023 | $517.45M | +32.2% |
| FY2022 | Dec 31, 2022 | $391.45M | +270.6% |
| FY2021 | Dec 31, 2021 | $105.61M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $786.80M | +116.9% |
| Q2 FY2026 | Jun 30, 2026 | $264.56M | +36.0% |
| Q1 FY2026 | Mar 31, 2026 | $293.60M | +33.7% |
| Q4 FY2025 | Dec 31, 2025 | $332.65M | +71.8% |
| Q3 FY2025 | Sep 30, 2025 | $362.74M | +44.7% |
| Q2 FY2025 | Jun 30, 2025 | $194.60M | -41.4% |
| Q1 FY2025 | Mar 31, 2025 | $219.68M | -47.4% |
| Q4 FY2024 | Dec 31, 2024 | $193.63M | -62.6% |
| Q3 FY2024 | Sep 30, 2024 | $250.71M | -46.3% |
| Q2 FY2024 | Jun 30, 2024 | $332.16M | -26.8% |
| Q1 FY2024 | Mar 31, 2024 | $417.46M | +2.3% |
| Q4 FY2023 | Dec 31, 2023 | $517.45M | +32.2% |
| Q3 FY2023 | Sep 30, 2023 | $466.58M | +157.2% |
| Q2 FY2023 | Jun 30, 2023 | $453.59M | +101.4% |
| Q1 FY2023 | Mar 31, 2023 | $407.96M | +48.7% |
| Q4 FY2022 | Dec 31, 2022 | $391.45M | +270.6% |
| Q3 FY2022 | Sep 30, 2022 | $181.44M | – |
| Q2 FY2022 | Jun 30, 2022 | $225.24M | – |
| Q1 FY2022 | Mar 31, 2022 | $274.44M | – |
| Q4 FY2021 | Dec 31, 2021 | $105.61M | – |
See a number that looks wrong?